Betting On Biosimilars In China? Think Again
This article was originally published in PharmAsia News
Executive Summary
Interchangeability, reimbursement, approval delays: as the issues keep piling up, will biosimilars offer attractive opportunities for pharma firms in China? Executives from front-running biotechs and legal experts shared their views at a recent meeting in Shanghai.
You may also be interested in...
Better Together: New Deal Adds Weight To China Biosimilar/Biobetter Swap
Perhaps encouraged by the recent successful initial public offering of Innovent Bio, more biologics developers in China are turning towards innovative biologics and away from traditional biosimilars.
Better Together: New Deal Adds Weight To China Biosimilar/Biobetter Swap
Perhaps encouraged by the recent successful initial public offering of Innovent Bio, more biologics developers in China are turning towards innovative biologics and away from traditional biosimilars.
What Lies Beneath China's Steep Price Cuts For New Drugs
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.
Need a specific report? 1000+ reports available
Buy Reports